An International Retrospective Observational Study Comparing Primary Cytoreductive Surgery With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Patients With Carcinoma of the Ovary, Fallopian Tubes and Peritoneum
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum.
• Patients \> 18 years old.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 at the time of the surgery.
• Invasive high-grade epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma in stage International Federation of Gynecology and Obstetrics (FIGO) IIIB-IVB (IVB only if resectable metastases are present), suspected or histologically confirmed and newly diagnosed.
• Patient underwent primary surgery or first course of neoadjuvant chemotherapy between January 1, 2018, and December 31, 2019.
• American Society of Anesthesiologists Physical Status Classification System (ASA) score 1 or 2 at the time of the surgery.
• Surgery performed by laparotomy with an attempt of maximal effort.
• The surgeon must be a certified or non-certified gynecologic oncologist.
• Based on all available information before the surgery (primary or interval), the patient was considered completely resectable.
• Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
• Preoperative imaging (either CT, whole-body MRI, or positron emission tomography (PET)-CT) excluding unresectable disease as per European Society of Gynaecological Oncology (ESGO) criteria.
• Surgical report on residual disease after surgery.